|
Behcet Syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the major genotype and haplotype of CD11a/CD18 may play a role in decreasing the susceptibility of BD, whereas the major genotype and haplotype of CD11c/CD18 may play a role in increasing the susceptibility of BD.
|
25155097 |
2014 |
|
Behcet Syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms of CD11a and CD11c have been suggested as susceptibility loci in Korean patients with Behçet's disease (BD).
|
27309860 |
2017 |
|
Behcet Syndrome
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
DEX, Col and ILalphaD in vitro differentially affected the stimulus-dependent oxidative burst of BD and caused the down-regulation of CD11a/CD18 surface expression in neutrophils but not monocytes.
|
16428075 |
2006 |
|
Acute Promyelocytic Leukemia
|
0.320 |
Biomarker
|
disease |
BEFREE |
In a test group of 58 APL patients, the most predictive immune profile was HLA-DR(low), CD11a(low) (alpha(L) subunit of the leukocyte integrin LFA-1), CD18(low) (beta(2) subunit of LFA-1).
|
15108165 |
2004 |
|
Acute Promyelocytic Leukemia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
ATRA was, however, incapable of promoting the up-regulation of CD11a in APL.
|
7815843 |
1994 |
|
Inflammatory Bowel Diseases
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Genetic associations with EN included known IBD susceptibility genes (PTGER4 [P = 8.8 × 10], ITGAL [0.03]) as well as SOCS5 (9.64 × 10), CD207 (3.14 × 10), ITGB3 (7.56 × 10), and rs6828740 (4q26) (P < 5.0 × 10).
|
24487271 |
2014 |
|
Psoriasis
|
0.130 |
Biomarker
|
disease |
BEFREE |
To better understand the relationship between the JCV life cycle and PML pathology, we studied autopsy brain tissue from a 70-year-old psoriasis patient on the integrin alpha-L inhibitor efalizumab following a ~2 month clinical course of PML.
|
27191595 |
2016 |
|
Psoriasis
|
0.130 |
Biomarker
|
disease |
BEFREE |
Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
|
22348003 |
2012 |
|
Psoriasis
|
0.130 |
Biomarker
|
disease |
BEFREE |
Targeting of the statin-binding site of LFA-1 could be used to treat diseases such as psoriasis, rheumatoid arthritis, ischemia/reperfusion injury and transplant rejection.
|
11385505 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
DNA demethylation and histone hyperacetylation of CD11a and CD70 regulatory regions contribute to the development of autoreactivity and autoantibody overstimulation in CD4(+) T cells of patients with systemic lupus erythematosus (SLE).
|
20223637 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have found a human serum, E27, obtained from a multiply transfused patient with systemic lupus erythematosus, which immunoprecipitates the lymphocyte function associated antigen-1 (LFA-1).
|
2438304 |
1987 |
|
Lupus Erythematosus, Systemic
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RFX1 can regulate epigenetic modifications of CD70 and CD11a and plays an important role in the development of SLE.
|
27283392 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated that histone demethylase JMJD3 regulates CD11a expression in lupus T cells by affecting the H3K27me3 levels in the ITGAL (CD11a) promoter region, and JMJD3 might thereby serve as a potential therapeutic target for SLE.
|
28430662 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that decreased ERK pathway signaling in T cells results in decreased expression of DNA methyltransferase 1 and overexpression of the methylation-sensitive genes CD11a and CD70, similar to T cells in human lupus.
|
18523434 |
2008 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apart from those classic methylation-sensitive autoimmunity-related genes in lupus, such as CD11a (ITGAL), Perforin (PRF1), CD70 (TNFSF7), CD40 ligand (TNFSF5) and PP2Acα, the genome-wide methylation pattern has also been explored recently, providing us a more and more full-scale picture of the abnormal status of DNA methylation in SLE.
|
23340289 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that PP2Acα represents a new methylation-sensitive gene that, like the previously reported CD70 and CD11a, contributes to the pathogenesis of SLE.
|
21346232 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Transfection of gadd45A small interfering RNA inhibited the autoreactivity of SLE CD4+ T cells and led to significant increases in the methylation levels of the CD11a and CD70 promoter regions.
|
20131288 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
H3K9 tri-methylation levels were significantly reduced within the CD11a and CD70 promoter regions in SLE CD4(+) T cells.
|
21192791 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA methylation changes occur in specific sequences that regulate LFA-1 expression in lupus T cells and in the hypomethylation model, indicating that altered methylation of specific genes may play a role in the pathogenesis of lupus.
|
12115234 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A T cell subset with similar CD11a expression was found in patients with active SLE.
|
1376122 |
1992 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The goal of this study was to comprehensively characterize CD4+CD28+ T cells overexpressing CD11a and KIR genes, and examine the relationship between this T cell subset, genetic risk, and disease activity in lupus.
|
29066026 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously reported that the immunohistochemically defined LFA-1 antigen (LFA-1-like antigen) was expressed on various exocrine tissues uninvolved with tumors in patients with malignant diseases using LFA-1 alpha-specific monoclonal antibodies (mAb) 2F12 and HVS6B6.
|
7497527 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using in vitro assays and an experimental orthotopic in vivo model of liver metastasis, we aimed to elucidate the role of tumor LFA-1 in the metastatic progression by means of the partial depletion of the β<sub>2</sub> subunit of LFA-1, required for integrin activation, firm adhesion and signaling.
|
29207960 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, we found a subset of PD-1 therapy-responsive CD8+ T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites.
|
29669928 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of CD8α, CD3ζ, granzyme K, CD28 and integrin αL RNAs was upregulated in HPV-positive lesions when compared with HPV-unrelated tumors (p < 0.05).
|
22890882 |
2013 |